Calliditas Therapeutics AB (CALT)

Market Cap	395.85M
Revenue (ttm)	33.64M
Net Income (ttm)	-59.62M
Shares Out	26.10M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	5.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,753
Open	14.93
Previous Close	14.12
Day's Range	14.93 - 15.24
52-Week Range	12.55 - 27.50
Beta	1.41
Analysts	Buy
Price Target	35.52 (+134.2%)
Earnings Date	Aug 18, 2022

About CALT

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary ...

• Industry: Biotechnology
• IPO Date: Jun 5, 2020
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: CALT

Full Company Profile

Financial Performance

In 2021, CALT's revenue was 229.35 million, an increase of 26,141.08% compared to the previous year's 874,000. Losses were -500.29 million, 15.4% more than in 2020.

Financial numbers in SEK Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CALT stock is "Buy." The 12-month stock price forecast is 35.52, which is an increase of 134.21% from the latest price.

Price Target

$35.52

(134.21% upside)

Analyst Consensus: Buy

Stock Forecasts